- Home
- HTO vs NRIX Comparison
HTO vs NRIX Comparison
Compare HTO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | NRIX |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | 837 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTO | NRIX |
|---|---|---|
| Price | $58.14 | $16.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $62.25 | $30.50 |
| AVG Volume (30 Days) | 462.6K | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | $40.12 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $43.75 | $8.20 |
| 52 Week High | $60.18 | $22.50 |
Technical Indicators
Market Signals| Indicator | HTO | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 56.34 |
| Support Level | $55.29 | $14.61 |
| Resistance Level | $59.00 | $16.47 |
| Average True Range (ATR) | 1.34 | 1.01 |
| MACD | -0.10 | 0.15 |
| Stochastic Oscillator | 56.68 | 67.63 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.